Miami, FL (May 25th, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company will be presenting at the annual meeting of the International Society of Cell and Gene Therapy (ISCT) taking place on May 26-28, 2021. [Read more…]
RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium
RoosterGEM™, a complete genetic engineering medium, empowers product developers to realize up to four-fold increased transduction efficiency in primary cells, and achieve a greater than 50% reduction in overall gene transfer cost.
Frederick, MD, May 20, 2021 – RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. [Read more…]
Organicell Signs An Exclusive Distribution Agreement With Apex Services In Pakistan
Miami, FL (May 19, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin™ to hospitals and clinics in the country. [Read more…]
Organicell Receives Approval In Pakistan For The Use Of Zofin™ For Compassionate Grounds For COVID-19
Clinical Trials To Commence Immediately
Miami, FL (May 11, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. [Read more…]
C-Stem™ outperforms 2D & aggregate cultures in benchmark of cell culture technologies for the mass-production of human induced pluripotent stem cells
TreeFrog Therapeutics presents new data at the 24th Annual Meeting of the American Society for Cell & Gene Therapy.
Bordeaux, France, May 11, 2021 – One month after announcing unprecedented exponential amplification of human pluripotent stem cells (hiPSCs) in a 10L bioreactor French cell therapy company, TreeFrog Therapeutics, released previously unpublished data at the 24th Annual Meeting of the American Society for Cell & Gene Therapy. The findings compare the continuous expansion over 28 days of human induced pluripotent stem cells (hiPSCs) in 2D cell culture, aggregate culture in bioreactor, and bioreactor-based C-StemTM technology. The benchmark demonstrates that C-StemTM outperforms both the 2D and aggregate cell cultures, with a cumulated amplification of over 151 millionfold over 28 days, achieved in only four passages. [Read more…]
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 117
- Next Page »